Reports Q1 revenue $20.49M, consensus $19.3M. “We are pleased with our strong start to the year as we further expanded our account base while benefiting from accelerated adoption of the Ceribell (CBLL) system,” said co-founder and CEO Jane Chao, Ph.D. “Looking ahead, we see 2025 as another momentous year of growth for Ceribell as we execute our proven playbook to drive adoption through physician education and continued investment in our commercial organization. We also look forward to offering our pediatric Clarity algorithm to customers while continuing to invest in our product development pipeline with the goal of ultimately making EEG a new vital sign.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell announces EEG system received full RedRAMP High authorization
- Ceribell, Inc.: Promising Growth Trajectory and Strong Market Potential Reinforce Buy Rating
- Ceribell announces FDA grants clearance for next-gen Ceribell Clarity algorithm
- Ceribell jumps after saying no impact from incremental tariffs until Q4
- Ceribell, Inc.: Strategic Resilience and Financial Health Amid Market Challenges